Dyadic International Stock Forecast, Price & News

-0.06 (-1.63 %)
(As of 06/14/2021 11:03 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume692 shs
Average Volume427,134 shs
Market Capitalization$99.75 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive DYAI News and Ratings via Email

Sign-up to receive the latest news and ratings for Dyadic International and its competitors with MarketBeat's FREE daily newsletter.

Dyadic International logo

About Dyadic International

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States. The company utilizes its patented and proprietary C1 technology and other technologies to conduct research, development, and commercial activities for the development and manufacturing of human and animal vaccines and drugs, such as virus like particles and antigens, monoclonal antibodies, fab antibody fragments, Fc-fusion proteins, biosimilars and/or biobetters, and other therapeutic enzymes and proteins. It offers DYAI-100, SARS-CoV-2-S-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial, is to validate to serve as proof of concept for the development of next generation multivariant COVID-19 vaccine candidates. The company has a research and development agreement with VTT Technical Research Centre of Finland, Ltd.; strategic research services agreement with Biotechnology Developments for Industry in Pharmaceuticals, S.L.U.; and research collaborations with Jiangsu Hengrui Medicine, Serum Institute of India Pvt., Ltd., and WuXi Biologics. It also has a collaboration with TurtleTree Scientific Pte. Ltd. to develop various recombinant protein growth factors; and a partnership with Medytox, Inc. to co-develop C1 manufactured COVID-19 vaccines and/or boosters. The company was founded in 1979 and is headquartered in Jupiter, Florida.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.29 out of 5 stars

Medical Sector

880th out of 2,099 stocks

Biological Products, Except Diagnostic Industry

127th out of 198 stocks

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Dyadic International (NASDAQ:DYAI) Frequently Asked Questions

Is Dyadic International a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dyadic International in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Dyadic International stock.
View analyst ratings for Dyadic International
or view top-rated stocks.

What stocks does MarketBeat like better than Dyadic International?

Wall Street analysts have given Dyadic International a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Dyadic International wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Dyadic International's next earnings date?

Dyadic International is scheduled to release its next quarterly earnings announcement on Thursday, June 17th 2021.
View our earnings forecast for Dyadic International

How were Dyadic International's earnings last quarter?

Dyadic International, Inc. (NASDAQ:DYAI) issued its quarterly earnings data on Monday, March, 29th. The biotechnology company reported ($0.07) earnings per share for the quarter, topping analysts' consensus estimates of ($0.08) by $0.01. Dyadic International had a negative net margin of 595.37% and a negative trailing twelve-month return on equity of 35.81%.
View Dyadic International's earnings history

How has Dyadic International's stock price been impacted by Coronavirus?

Dyadic International's stock was trading at $4.72 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, DYAI shares have decreased by 23.3% and is now trading at $3.62.
View which stocks have been most impacted by COVID-19

What price target have analysts set for DYAI?

1 brokerages have issued 12 month price objectives for Dyadic International's stock. Their forecasts range from $11.00 to $11.00. On average, they expect Dyadic International's stock price to reach $11.00 in the next twelve months. This suggests a possible upside of 203.9% from the stock's current price.
View analysts' price targets for Dyadic International
or view top-rated stocks among Wall Street analysts.

Who are Dyadic International's key executives?

Dyadic International's management team includes the following people:
  • Mr. Mark A. Emalfarb, Founder, CEO, Pres & Director (Age 65, Pay $724.29k)
  • Ms. Ping Wang Rawson, Chief Financial Officer (Age 45, Pay $301.09k)
  • Mr. Matthew S. Jones, Managing Director of Bus. Devel. & Licensing (Age 43, Pay $365.32k)
  • Dr. Ronen Tchelet, VP of Research & Bus. Devel. (Age 63, Pay $259.92k)
  • Ms. Ana Gómez Rodriguez, Sec. of the Board

Who are some of Dyadic International's key competitors?

What other stocks do shareholders of Dyadic International own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Dyadic International investors own include Silvercorp Metals (SVM), Endeavour Silver (EXK), Hecla Mining (HL), Pfizer (PFE), Advanced Micro Devices (AMD), Endeavour Silver (EDR), Mandalay Resources (MND), Ampio Pharmaceuticals (AMPE), Alibaba Group (BABA) and Chimerix (CMRX).

What is Dyadic International's stock symbol?

Dyadic International trades on the NASDAQ under the ticker symbol "DYAI."

Who are Dyadic International's major shareholders?

Dyadic International's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (4.74%), Geode Capital Management LLC (1.20%), Northern Trust Corp (0.88%), Axiom Investment Management LLC (0.24%), Axiom Investment Management LLC (0.24%) and Nuveen Asset Management LLC (0.24%). Company insiders that own Dyadic International stock include Barry Buckland, Mark A Emalfarb, Ping Wang Rawson and Ronen Tchelet.
View institutional ownership trends for Dyadic International

Which institutional investors are selling Dyadic International stock?

DYAI stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp, JPMorgan Chase & Co., and Nuveen Asset Management LLC.
View insider buying and selling activity for Dyadic International
or view top insider-selling stocks.

Which institutional investors are buying Dyadic International stock?

DYAI stock was purchased by a variety of institutional investors in the last quarter, including Axiom Investment Management LLC, Axiom Investment Management LLC, BlackRock Inc., Geode Capital Management LLC, Renaissance Technologies LLC, Barclays PLC, Forefront Analytics LLC, and Perkins Capital Management Inc..
View insider buying and selling activity for Dyadic International
or or view top insider-buying stocks.

How do I buy shares of Dyadic International?

Shares of DYAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Dyadic International's stock price today?

One share of DYAI stock can currently be purchased for approximately $3.62.

How much money does Dyadic International make?

Dyadic International has a market capitalization of $99.75 million and generates $1.60 million in revenue each year.

How many employees does Dyadic International have?

Dyadic International employs 6 workers across the globe.

What is Dyadic International's official website?

The official website for Dyadic International is

Where are Dyadic International's headquarters?

Dyadic International is headquartered at 140 INTRACOASTAL POINTE DRIVE SUITE 404, JUPITER FL, 33477.

How can I contact Dyadic International?

Dyadic International's mailing address is 140 INTRACOASTAL POINTE DRIVE SUITE 404, JUPITER FL, 33477. The biotechnology company can be reached via phone at 561-743-8333 or via email at [email protected]

This page was last updated on 6/14/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.